Cargando…

Specification, validation, and adherence of quality indicators to optimize the safe use of nonsteroidal anti-inflammatory drugs for knee osteoarthritis pain in the primary care setting

BACKGROUND: Nonsteroidal anti-inflammatory drugs (NSAIDs) used for osteoarthritis (OA) in primary care may cause gastrointestinal or renal injury. This study estimated adherence to two quality indicators (QIs) to optimize NSAID safety: add proton pump inhibitors (PPI) to NSAIDs for patients with gas...

Descripción completa

Detalles Bibliográficos
Autores principales: Swan, Joshua T., Rizk, Elsie, Duong, Phuong Y, Alghamdi, Bader M., Kaur, Navjot, Nagaraj, Sudha, Brown, Anthony E., Flores, Eleazar, Spence, Nathan, Tajchman, Sharla
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10523610/
https://www.ncbi.nlm.nih.gov/pubmed/37759196
http://dx.doi.org/10.1186/s12891-023-06904-x
_version_ 1785110597057118208
author Swan, Joshua T.
Rizk, Elsie
Duong, Phuong Y
Alghamdi, Bader M.
Kaur, Navjot
Nagaraj, Sudha
Brown, Anthony E.
Flores, Eleazar
Spence, Nathan
Tajchman, Sharla
author_facet Swan, Joshua T.
Rizk, Elsie
Duong, Phuong Y
Alghamdi, Bader M.
Kaur, Navjot
Nagaraj, Sudha
Brown, Anthony E.
Flores, Eleazar
Spence, Nathan
Tajchman, Sharla
author_sort Swan, Joshua T.
collection PubMed
description BACKGROUND: Nonsteroidal anti-inflammatory drugs (NSAIDs) used for osteoarthritis (OA) in primary care may cause gastrointestinal or renal injury. This study estimated adherence to two quality indicators (QIs) to optimize NSAID safety: add proton pump inhibitors (PPI) to NSAIDs for patients with gastrointestinal (GI) risk (QI #1 NSAID-PPI) and avoid oral NSAIDs in chronic kidney disease (CKD) stage G4 or G5 (QI #2 NSAID-CKD). METHODS: This retrospective study included index primary care clinic visits for knee OA at our health system in 2019. The validation cohort consisted of a random sample of 60 patients. The remainder were included in the expanded cohort. Analysis of structured data extracts was validated against chart review of clinic visit notes (validation cohort) and estimated QI adherence (expanded cohort). RESULTS: Among 60 patients in the validation cohort, analysis of data extracts was validated against chart review for QI #1 NSAID-PPI (100% sensitivity and 91% specificity) and QI #2 NSAID-CKD (100% accuracy). Among 335 patients in the expanded cohort, 44% used NSAIDs, 27% used PPIs, 73% had elevated GI risk, and only 2% had CKD stage 4 or 5. Twenty-one percent used NSAIDs and had elevated GI risk but were not using PPIs. Therefore, adherence to QI #1 NSAID-PPI was 79% (95% CI, 74–83%). No patients with CKD stage 4 or 5 used NSAIDs. Therefore, adherence to QI #2 NSAID-CKD was 100%. CONCLUSION: A substantial proportion of knee OA patients with GI risk factors did not receive PPI with NSAID therapy during primary care visits. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12891-023-06904-x.
format Online
Article
Text
id pubmed-10523610
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-105236102023-09-28 Specification, validation, and adherence of quality indicators to optimize the safe use of nonsteroidal anti-inflammatory drugs for knee osteoarthritis pain in the primary care setting Swan, Joshua T. Rizk, Elsie Duong, Phuong Y Alghamdi, Bader M. Kaur, Navjot Nagaraj, Sudha Brown, Anthony E. Flores, Eleazar Spence, Nathan Tajchman, Sharla BMC Musculoskelet Disord Research BACKGROUND: Nonsteroidal anti-inflammatory drugs (NSAIDs) used for osteoarthritis (OA) in primary care may cause gastrointestinal or renal injury. This study estimated adherence to two quality indicators (QIs) to optimize NSAID safety: add proton pump inhibitors (PPI) to NSAIDs for patients with gastrointestinal (GI) risk (QI #1 NSAID-PPI) and avoid oral NSAIDs in chronic kidney disease (CKD) stage G4 or G5 (QI #2 NSAID-CKD). METHODS: This retrospective study included index primary care clinic visits for knee OA at our health system in 2019. The validation cohort consisted of a random sample of 60 patients. The remainder were included in the expanded cohort. Analysis of structured data extracts was validated against chart review of clinic visit notes (validation cohort) and estimated QI adherence (expanded cohort). RESULTS: Among 60 patients in the validation cohort, analysis of data extracts was validated against chart review for QI #1 NSAID-PPI (100% sensitivity and 91% specificity) and QI #2 NSAID-CKD (100% accuracy). Among 335 patients in the expanded cohort, 44% used NSAIDs, 27% used PPIs, 73% had elevated GI risk, and only 2% had CKD stage 4 or 5. Twenty-one percent used NSAIDs and had elevated GI risk but were not using PPIs. Therefore, adherence to QI #1 NSAID-PPI was 79% (95% CI, 74–83%). No patients with CKD stage 4 or 5 used NSAIDs. Therefore, adherence to QI #2 NSAID-CKD was 100%. CONCLUSION: A substantial proportion of knee OA patients with GI risk factors did not receive PPI with NSAID therapy during primary care visits. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12891-023-06904-x. BioMed Central 2023-09-27 /pmc/articles/PMC10523610/ /pubmed/37759196 http://dx.doi.org/10.1186/s12891-023-06904-x Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Swan, Joshua T.
Rizk, Elsie
Duong, Phuong Y
Alghamdi, Bader M.
Kaur, Navjot
Nagaraj, Sudha
Brown, Anthony E.
Flores, Eleazar
Spence, Nathan
Tajchman, Sharla
Specification, validation, and adherence of quality indicators to optimize the safe use of nonsteroidal anti-inflammatory drugs for knee osteoarthritis pain in the primary care setting
title Specification, validation, and adherence of quality indicators to optimize the safe use of nonsteroidal anti-inflammatory drugs for knee osteoarthritis pain in the primary care setting
title_full Specification, validation, and adherence of quality indicators to optimize the safe use of nonsteroidal anti-inflammatory drugs for knee osteoarthritis pain in the primary care setting
title_fullStr Specification, validation, and adherence of quality indicators to optimize the safe use of nonsteroidal anti-inflammatory drugs for knee osteoarthritis pain in the primary care setting
title_full_unstemmed Specification, validation, and adherence of quality indicators to optimize the safe use of nonsteroidal anti-inflammatory drugs for knee osteoarthritis pain in the primary care setting
title_short Specification, validation, and adherence of quality indicators to optimize the safe use of nonsteroidal anti-inflammatory drugs for knee osteoarthritis pain in the primary care setting
title_sort specification, validation, and adherence of quality indicators to optimize the safe use of nonsteroidal anti-inflammatory drugs for knee osteoarthritis pain in the primary care setting
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10523610/
https://www.ncbi.nlm.nih.gov/pubmed/37759196
http://dx.doi.org/10.1186/s12891-023-06904-x
work_keys_str_mv AT swanjoshuat specificationvalidationandadherenceofqualityindicatorstooptimizethesafeuseofnonsteroidalantiinflammatorydrugsforkneeosteoarthritispainintheprimarycaresetting
AT rizkelsie specificationvalidationandadherenceofqualityindicatorstooptimizethesafeuseofnonsteroidalantiinflammatorydrugsforkneeosteoarthritispainintheprimarycaresetting
AT duongphuongy specificationvalidationandadherenceofqualityindicatorstooptimizethesafeuseofnonsteroidalantiinflammatorydrugsforkneeosteoarthritispainintheprimarycaresetting
AT alghamdibaderm specificationvalidationandadherenceofqualityindicatorstooptimizethesafeuseofnonsteroidalantiinflammatorydrugsforkneeosteoarthritispainintheprimarycaresetting
AT kaurnavjot specificationvalidationandadherenceofqualityindicatorstooptimizethesafeuseofnonsteroidalantiinflammatorydrugsforkneeosteoarthritispainintheprimarycaresetting
AT nagarajsudha specificationvalidationandadherenceofqualityindicatorstooptimizethesafeuseofnonsteroidalantiinflammatorydrugsforkneeosteoarthritispainintheprimarycaresetting
AT brownanthonye specificationvalidationandadherenceofqualityindicatorstooptimizethesafeuseofnonsteroidalantiinflammatorydrugsforkneeosteoarthritispainintheprimarycaresetting
AT floreseleazar specificationvalidationandadherenceofqualityindicatorstooptimizethesafeuseofnonsteroidalantiinflammatorydrugsforkneeosteoarthritispainintheprimarycaresetting
AT spencenathan specificationvalidationandadherenceofqualityindicatorstooptimizethesafeuseofnonsteroidalantiinflammatorydrugsforkneeosteoarthritispainintheprimarycaresetting
AT tajchmansharla specificationvalidationandadherenceofqualityindicatorstooptimizethesafeuseofnonsteroidalantiinflammatorydrugsforkneeosteoarthritispainintheprimarycaresetting